Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Ris-Rez (GSK5764227) vs topotecan in relapsed ES-SCLC
jRCT2071250052Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan in small cell lung cancer (SCLC) (2 arms), sponsored by GSK. Primary endpoint: Overall Survival (OS). Started Oct 2025; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071250052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250052.